Membrane interaction of islet amyloid polypeptide

Biochimica et Biophysica Acta - Biomembranes

Volumn 1768, Issue 8, 2007, Pages 2002-2009

  Jayasinghe, Sajith A ^a   Langen, Ralf ^b  

^a CALIFORNIA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Aggregation; IAPP; Islet amyloid polypeptide; Membrane damage; Membranes

Indexed keywords

AMYLOID PROTEIN; POLYPEPTIDE;

HUMAN; LIPID COMPOSITION; LIPID MEMBRANE; MEMBRANE DAMAGE; MEMBRANE PERMEABILITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET CELL; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FOLDING; PROTEIN INTERACTION; REVIEW;

AMYLOID; ANIMALS; CATALYSIS; CELL MEMBRANE; CELL MEMBRANE PERMEABILITY; CYTOTOXINS; DIABETES MELLITUS, TYPE 2; HUMANS; LIPID METABOLISM; PROTEIN FOLDING;

EID: 34547152267     PISSN: 00052736     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamem.2007.01.022     Document Type: Review

References (93)

1. C.f.D.C.a. Prevention. National Diabetes Statistics Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2005 (2005), U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, GA
2. Biondi-Zoccai G.G., Abbate A., Liuzzo G., and Biasucci L.M. Atherothrombosis, inflammation, and diabetes. J. Am. Coll. Cardiol. 41 (2003) 1071-1077
3. Grundy S.M., Benjamin I.J., Burke G.L., Chait A., Eckel R.H., Howard B.V., Mitch W., Smith Jr. S.C., and Sowers J.R. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 100 (1999) 1134-1146
4. Hull R.L., Westermark G.T., Westermark P., and Kahn S.E. Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes. J. Clin. Endocr. Metab. 89 (2004) 3629-3643
5. Kahn S.E., Andrikopoulos S., and Verchere C.B. Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes. Diabetes 48 2 (1999) 241-253
6. Opie E.L. The relation of diabetes mellitus to lesions of the pancrease: hayaline degeneration of the islands of Langerhans. J. Exp. Med. 5 (1901) 527-554
7. Ehrlich J.C., and Ratner I.M. Amyloidosis of the islets of Langerhans. A restudy of islet hyalin in diabetic and non-diabetic individuals. Am. J. Pathol. 38 (1961) 49-59
8. Cooper G.J., Willis A.C., Clark A., Turner R.C., Sim R.B., and Reid K.B. Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc. Natl. Acad. Sci. U. S. A. 84 23 (1987) 8628-8632
9. Westermark P., Wernstedt C., O'Brien T.D., Hayden D.W., and Johnson K.H. Islet amyloid in type 2 human diabetes mellitus and adult diabetic cats contains a novel putative polypeptide hormone. Am. J. Pathol. 127 3 (1987) 414-417
10. Kahn S.E., D'Alessio D.A., Schwartz M.W., Fujimoto W.Y., Ensinck J.W., Taborsky Jr. G.J., and Porte Jr. D. Evidence of cosecretion of islet amyloid polypeptide and insulin by beta-cells. Diabetes 39 (1990) 634-638
11. Butler P.C., Chou J., Carter W.B., Wang Y.N., Bu B.H., Chang D., Chang J.K., and Rizza R.A. Effects of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic humans. Diabetes 39 (1990) 752-756
12. Cooper G.J., Leighton B., Dimitriadis G.D., Parry-Billings M., Kowalchuk J.M., Howland K., Rothbard J.B., Willis A.C., and Reid K.B. Amylin found in amyloid deposits in human type 2 diabetes mellitus may be a hormone that regulates glycogen metabolism in skeletal muscle. Proc. Natl. Acad. Sci. U. S. A. 85 (1988) 7763-7766
13. Arnelo U., Permert J., Larsson J., Reidelberger R.D., Arnelo C., and Adrian T.E. Chronic low dose islet amyloid polypeptide infusion reduces food intake, but does not influence glucose metabolism, in unrestrained conscious rats: studies using a novel aortic catheterization technique. Endocrinology 138 (1997) 4081-4085
14. Dacquin R., Davey R.A., Laplace C., Levasseur R., Morris H.A., Goldring S.R., Gebre-Medhin S., Galson D.L., Zajac J.D., and Karsenty G. Amylin inhibits bone resorption while the calcitonin receptor controls bone formation in vivo. J. Cell Biol. 164 (2004) 509-514
15. Gebre-Medhin S., Mulder H., Pekny M., Westermark G., Tornell J., Westermark P., Sundler F., Ahren B., and Betsholtz C. Increased insulin secretion and glucose tolerance in mice lacking islet amyloid polypeptide (amylin). Biochem. Biophys. Res. Co. 250 (1998) 271-277
16. Rushing P.A., Hagan M.M., Seeley R.J., Lutz T.A., and Woods S.C. Amylin: a novel action in the brain to reduce body weight. Endocrinology 141 (2000) 850-853
17. Janson J., Ashley R.H., Harrison D., McIntyre S., and Butler P.C. The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes 48 3 (1999) 491-498
18. Ritzel R.A., and Butler P.C. Replication increases beta-cell vulnerability to human islet amyloid polypeptide-induced apoptosis. Diabetes 52 (2003) 1701-1708
19. Lorenzo A., Razzaboni B., Weir G.C., and Yankner B.A. Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature 368 (1994) 756-760
20. O'Brien T.D., Butler P.C., Kreutter D.K., Kane L.A., and Eberhardt N.L. Human islet amyloid polypeptide expression in COS-1 cells. A model of intracellular amyloidogenesis. Am. J. Pathol. 147 3 (1995) 609-616
21. Hiddinga H.J., and Eberhardt N.L. Intracellular amyloidogenesis by human islet amyloid polypeptide induces apoptosis in COS-1 cells. Am. J. Pathol. 154 4 (1999) 1077-1088
22. Westermark P., Engstrèom U., Johnson K.H., Westermark G.T., and Betsholtz C. Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proc. Natl. Acad. Sci. U. S. A. 87 13 (1990) 5036-5040
23. Janson J., Soeller W.C., Roche P.C., Nelson R.T., Torchia A.J., Kreutter D.K., and Butler P.C. Spontaneous diabetes mellitus in transgenic mice expressing human islet amyloid polypeptide. Proc. Natl. Acad. Sci. U. S. A. 93 14 (1996) 7283-7288
24. Butler A.E., Jang J., Gurlo T., Carty M.D., Soeller W.C., and Butler P.C. Diabetes due to a progressive defect in beta-cell mass in rats transgenic for human islet amyloid polypeptide (HIP Rat): a new model for type 2 diabetes. Diabetes 53 (2004) 1509-1516
25. Verchere C.B., D'Alessio D.A., Palmiter R.D., Weir G.C., Bonner-Weir S., Baskin D.G., and Kahn S.E. Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic beta cell expression of human islet amyloid polypeptide. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 3492-3496
26. Soeller W.C., Janson J., Hart S.E., Parker J.C., Carty M.D., Stevenson R.W., Kreutter D.K., and Butler P.C. Islet amyloid-associated diabetes in obese A(vy)/a mice expressing human islet amyloid polypeptide. Diabetes 47 (1998) 743-750
27. Hoppener J.W., Oosterwijk C., Nieuwenhuis M.G., Posthuma G., Thijssen J.H., Vroom T.M., Ahren B., and Lips C.J. Extensive islet amyloid formation is induced by development of Type II diabetes mellitus and contributes to its progression: pathogenesis of diabetes in a mouse model. Diabetologia 42 (1999) 427-434
28. Butler A.E., Janson J., Soeller W.C., and Butler P.C. Increased beta-cell apoptosis prevents adaptive increase in beta-cell mass in mouse model of type 2 diabetes: evidence for role of islet amyloid formation rather than direct action of amyloid. Diabetes 52 9 (2003) 2304-2314
29. Sakagashira S., Sanke T., Hanabusa T., Shimomura H., Ohagi S., Kumagaye K.Y., Nakajima K., and Nanjo K. Missense mutation of amylin gene (S20G) in Japanese NIDDM patients. Diabetes 45 (1996) 1279-1281
30. Sakagashira S., Hiddinga H.J., Tateishi K., Sanke T., Hanabusa T., Nanjo K., and Eberhardt N.L. S20G mutant amylin exhibits increased in vitro amyloidogenicity and increased intracellular cytotoxicity compared to wild-type amylin. Am. J. Pathol. 157 (2000) 2101-2109
31. Ma Z., Westermark G.T., Sakagashira S., Sanke T., Gustavsson A., Sakamoto H., Engstrom U., Nanjo K., and Westermark P. Enhanced in vitro production of amyloid-like fibrils from mutant (S20G) islet amyloid polypeptide. Amyloid 8 (2001) 242-249
32. Jaikaran E.T., Higham C.E., Serpell L.C., Zurdo J., Gross M., Clark A., and Fraser P.E. Identification of a novel human islet amyloid polypeptide beta-sheet domain and factors influencing fibrillogenesis. J. Mol. Biol. 308 3 (2001) 515-525
33. Higham C.E., Jaikaran E.T., Fraser P.E., Gross M., and Clark A. Preparation of synthetic human islet amyloid polypeptide (IAPP) in a stable conformation to enable study of conversion to amyloid-like fibrils. FEBS Lett. 470 1 (2000) 55-60
34. Kayed R., Bernhagen J., Greenfield N., Sweimeh K., Brunner H., Voelter W., and Kapurniotu A. Conformational transitions of islet amyloid polypeptide (IAPP) in amyloid formation in vitro. J. Mol. Biol. 287 4 (1999) 781-796
35. Makin O.S., and Serpell L.C. Structural characterisation of islet amyloid polypeptide fibrils. J. Mol. Biol. 335 (2004) 1279-1288
36. Jayasinghe S.A., and Langen R. Identifying structural features of fibrillar islet amyloid polypeptide using site-directed spin labeling. J. Biol. Chem. 279 (2004) 48420-48425
37. Torok M., Milton S., Kayed R., Wu P., McIntire T., Glabe C.G., and Langen R. Structural and dynamic features of Alzheimer's Abeta peptide in amyloid fibrils studied by site-directed spin labeling. J. Biol. Chem. 277 43 (2002) 40810-40815
38. Der-Sarkissian A., Jao C.C., Chen J., and Langen R. Structural organization of alpha-synuclein fibrils studied by site-directed spin labeling. J. Biol. Chem. 278 39 (2003) 37530-37535
39. Margittai M., and Langen R. Template assisted filament growth by parallel stacking of tau. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 10278-10283
40. Petkova A.T., Ishii Y., Balbach J.J., Antzutkin O.N., Leapman R.D., Delaglio F., and Tycko R. A structural model for Alzheimer's beta-amyloid fibrils based on experimental constraints from solid state NMR. Proc. Natl. Acad. Sci. U. S. A. 99 26 (2002) 16742-16747
41. Chan J.C., Oyler N.A., Yau W.M., and Tycko R. Parallel beta-sheets and polar zippers in amyloid fibrils formed by residues 10-39 of the yeast prion protein Ure2p. Biochemistry 44 (2005) 10669-10680
42. Caughey B., and Lansbury P.T. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu. Rev. Neurosci. 26 (2003) 267-298
43. Kayed R., Head E., Thompson J.L., McIntire T.M., Milton S.C., Cotman C.W., and Glabe C.G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300 (2003) 486-489
44. Kurganov B., Doh M., and Arispe N. Aggregation of liposomes induced by the toxic peptides Alzheimer's Aβs, human amylin and prion (106-126): facilitation by membrane-bound GM1 ganglioside. Peptides 25 (2004) 217-232
45. Kazlauskaite J., Sanghera N., Sylvester I., Venien-Bryan C., and Pinheiro T.J. Structural changes of the prion protein in lipid membranes leading to aggregation and fibrillization. Biochemistry 42 (2003) 3295-3304
46. Matsuzaki K., and Horikiri C. Interactions of amyloid b-peptide (1-40) with ganglioside-containing membranes. Biochemistry 38 (1999) 4137-4142
47. Davidson W.S., Jonas A., Clayton D.F., and George J.M. Stabilization of a-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem. 273 (1998) 9443-9449
48. Knight J.D., and Miranker A.D. Phospholipid catalysis of diabetic amyloid assembly. J. Mol. Biol. 341 (2004) 1175-1187
49. Bokvist M., Lindstrom F., Watts A., and Grobner G. Two types of Alzheimer's b-amyloid (1-40) peptide membrane interactions: aggregation preventing transmembrane anchoring versus accelerated surface fibril formation. J. Mol. Biol. 335 (2004) 1039-1049
50. Chirita C.N., Necula M., and Kuret J. Anionic micelles and vesicles induce tau fibrillization in vitro. J. Biol. Chem. 278 (2003) 25644-25650
51. Necula M., Chirita C.N., and Kuret J. Rapid anionic micelle-mediated a-synuclein fibrillization in vitro. J. Biol. Chem. 278 (2003) 46674-46680
52. Lee H.J., Choi C., and Lee S.J. Membrane-bound a-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form. J. Biol. Chem. 277 (2002) 671-678
53. Anguiano M., Nowak R.J., and Lansbury Jr. P.T. Protofibrillar islet amyloid polypeptide permeabilizes synthetic vesicles by a pore-like mechanism that may be relevant to type II diabetes. Biochemistry 41 (2002) 11338-11343
54. Arispe N., Pollard H.B., and Rojas E. Giant multilevel cation channels formed by Alzheimer disease amyloid beta-protein [AbP-(1-40)] in bilayer membranes. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 10573-10577
55. Volles M.J., Lee S.J., Rochet J.C., Shtilerman M.D., Ding T.T., Kessler J.C., and Lansbury Jr. P.T. Vesicle permeabilization by protofibrillar a-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 40 (2001) 7812-7819
56. Lashuel H.A., and Lansbury P.T. Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins?. Q. Rev. Biophys. (2006) 1-35
57. Knight J.D., Hebda J.A., and Miranker A.D. Conserved and cooperative assembly of membrane-bound alpha-helical states of islet amyloid polypeptide. Biochemistry 45 (2006) 9496-9508
58. Jayasinghe S.A., and Langen R. Lipid membranes modulate the structure of islet amyloid polypeptide. Biochemistry 44 (2005) 12113-12119
59. Sparr E., Engel M.F., Sakharov D.V., Sprong M., Jacobs J., de Kruijff B., Hoppener J.W., and Killian J.A. Islet amyloid polypeptide-induced membrane leakage involves uptake of lipids by forming amyloid fibers. FEBS Lett. 577 (2004) 117-120
60. Rustenbeck I., Matthies A., and Lenzen S. Lipid composition of glucose-stimulated pancreatic islets and insulin-secreting tumor cells. Lipids 29 (1994) 685-692
61. Gennis R.B. Biomembranes: Molecular Structure and Function (1989), Springer-Verlag
62. de Koning E.J., Morris E.R., Hofhuis F.M., Posthuma G., Hoppener J.W., Morris J.F., Capel P.J., Clark A., and Verbeek J.S. Intra- and extracellular amyloid fibrils are formed in cultured pancreatic islets of transgenic mice expressing human islet amyloid polypeptide. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 8467-8471
63. Ma Z., and Westermark G.T. Effects of free fatty acid on polymerization of islet amyloid polypeptide (IAPP) in vitro and on amyloid fibril formation in cultivated isolated islets of transgenic mice overexpressing human IAPP. Mol. Med. 8 (2002) 863-868
64. Ladokhin A.S., and White S.H. Folding of amphipathic alpha-helices on membranes: energetics of helix formation by melittin. J. Mol. Biol. 285 (1999) 1363-1369
65. Kaiser E.T., and Kezdy F.J. Secondary structures of proteins and peptides in amphiphilic environments. (A review). Proc. Natl. Acad. Sci. U. S. A. 80 (1983) 1137-1143
66. White S.H., and Wimley W.C. Membrane protein folding and stability: physical principles. Annu. Rev. Biophys. Biomol. 28 (1999) 319-365
67. Wimley W.C., Hristova K., Ladokhin A.S., Silvestro L., Axelsen P.H., and White S.H. Folding of b-sheet membrane proteins: a hydrophobic hexapeptide model. J. Mol. Biol. 277 (1998) 1091-1110
68. Wimalawansa S.J. Amylin, calcitonin gene-related peptide, calcitonin, and adrenomedullin: a peptide superfamily. Cit. Rev. Neurobiol. 11 (1997) 167-239
69. Motta A., Andreotti G., Amodeo P., Strazzullo G., and Castiglione Morelli M.A. Solution structure of human calcitonin in membrane-mimetic environment: the role of the amphipathic helix. Proteins 32 (1998) 314-323
70. Breeze A.L., Harvey T.S., Bazzo R., and Campbell I.D. Solution structure of human calcitonin gene-related peptide by 1H NMR and distance geometry with restrained molecular dynamics. Biochemistry 30 (1991) 575-582
71. Tenidis K., Waldner M., Bernhagen J., Fischle W., Bergmann M., Weber M., Merkle M.L., Voelter W., Brunner H., and Kapurniotu A. Identification of a penta- and hexapeptide of islet amyloid polypeptide (IAPP) with amyloidogenic and cytotoxic properties. J. Mol. Biol. 295 (2000) 1055-1071
72. Moriarty D.F., and Raleigh D.P. Effects of sequential proline substitutions on amyloid formation by human amylin20-29. Biochemistry 38 (1999) 1811-1818
73. Mirzabekov T.A., Lin M.C., and Kagan B.L. Pore formation by the cytotoxic islet amyloid peptide amylin. J. Biol. Chem. 271 (1996) 1988-1992
74. Quist A., Doudevski I., Lin H., Azimova R., Ng D., Frangione B., Kagan B., Ghiso J., and Lal R. Amyloid ion channels: a common structural link for protein-misfolding disease. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 10427-10432
75. Kawahara M., Kuroda Y., Arispe N., and Rojas E. Alzheimer's beta-amyloid, human islet amylin, and prion protein fragment evoke intracellular free calcium elevations by a common mechanism in a hypothalamic GnRH neuronal cell line. J. Biol. Chem. 275 (2000) 14077-14083
76. Anguiano M., Nowak R.J., and Lansbury Jr. P.T. Protofibrillar islet amyloid polypeptide permeabilizes synthetic vesicles by a pore-like mechanism that may be relevant to type II diabetes. Biochemistry 41 38 (2002) 11338-11343
77. Porat Y., Kolusheva S., Jelinek R., and Gazit E. The human islet amyloid polypeptide forms transient membrane-active prefibrillar assemblies. Biochemistry 42 37 (2003) 10971-10977
78. Harroun T.A., Bradshaw J.P., and Ashley R.H. Inhibitors can arrest the membrane activity of human islet amyloid polypeptide independently of amyloid formation. FEBS Lett. 507 (2001) 200-204
79. Green J.D., Kreplak L., Goldsbury C., Li Blatter X., Stolz M., Cooper G.S., Seelig A., Kistler J., and Aebi U. Atomic force microscopy reveals defects within mica supported lipid bilayers induced by the amyloidogenic human amylin peptide. J. Mol. Biol. 342 (2004) 877-887
80. Shai Y. Mechanism of the binding, insertion and destabilization of phospholipid bilayer membranes by alpha-helical antimicrobial and cell non-selective membrane-lytic peptides. Biochim. Biophys. Acta 1462 (1999) 55-70
81. Ladokhin A.S., Selsted M.E., and White S.H. Sizing membrane pores in lipid vesicles by leakage of co-encapsulated markers: pore formation by melittin. Biophys. J. 72 (1997) 1762-1766
82. Ladokhin A.S., and White S.H. 'Detergent-like' permeabilization of anionic lipid vesicles by melittin. Biochim. Biophys. Acta 1514 (2001) 253-260
83. Wimley W.C., Selsted M.E., and White S.H. Interactions between human defensins and lipid bilayers: evidence for formation of multimeric pores. Protein Sci. 3 (1994) 1362-1373
84. Hristova K., Selsted M.E., and White S.H. Critical role of lipid composition in membrane permeabilization by rabbit neutrophil defensins. J. Biol. Chem. 272 (1997) 24224-24233
85. Lashuel H.A., Hartley D., Petre B.M., Walz T., and Lansbury Jr. P.T. Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 418 (2002) 291
86. Lashuel H.A., Petre B.M., Wall J., Simon M., Nowak R.J., Walz T., and Lansbury Jr. P.T. Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J. Mol. Biol. 322 (2002) 1089-1102
87. Ding T.T., Lee S.J., Rochet J.C., and Lansbury Jr. P.T. Annular alpha-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes. Biochemistry 41 (2002) 10209-10217
88. Lashuel H.A., Hartley D.M., Petre B.M., Wall J.S., Simon M.N., Walz T., and Lansbury Jr. P.T. Mixtures of wild-type and a pathogenic (E22G) form of Abeta40 in vitro accumulate protofibrils, including amyloid pores. J. Mol. Biol. 332 (2003) 795-808
89. Balali-Mood K., Ashley R.H., Hauss T., and Bradshaw J.P. Neutron diffraction reveals sequence-specific membrane insertion of pre-fibrillar islet amyloid polypeptide and inhibition by rifampicin. FEBS Lett. 579 (2005) 1143-1148
90. Kayed R., Sokolov Y., Edmonds B., McIntire T.M., Milton S.C., Hall J.E., and Glabe C.G. Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J. Biol. Chem. 279 (2004) 46363-46366
91. Gellermann G.P., Appel T.R., Tannert A., Radestock A., Hortschansky P., Schroeckh V., Leisner C., Lutkepohl T., Shtrasburg S., Rocken C., Pras M., Linke R.P., Diekmann S., and Fandrich M. Raft lipids as common components of human extracellular amyloid fibrils. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 6297-6302
92. Engel M.F., Yigittop H., Elgersma R.C., Rijkers D.T., Liskamp R.M., de Kruijff B., Hoppener J.W., and Killian J.A. Islet amyloid polypeptide inserts into phospholipid monolayers as a monomer. J. Mol. Biol. 356 (2006) 783-789
93. Li S.C., and Deber C.M. A measure of helical propensity for amino acids in membrane environments. Nat. Struct. Biol. 1 (1994) 368-373